The Arlington, Virginia–based nonprofit American Association of Pharmaceutical Scientists (AAPS) will launch two Innovator-Curated tracks at its 2026 PharmSci 360 conference, scheduled for October 25–28, 2026, at the Ernest N. Morial Convention Center in New Orleans, Louisiana. The organization announced that the tracks will explore the current state of scientific research integrity in an AI…
A decade in the making: How functional NAMs are redefining cardiac safety assessment
In recent years, the momentum behind New Approach Methodologies (NAMs) in drug safety testing has accelerated rapidly. Driven by regulatory initiatives, evolving guidance, and growing internal pressure within pharmaceutical organizations, this acceleration can make it feel as though NAM adoption has arrived suddenly, almost overnight. When the FDA Modernization Act 2.0 was signed into law…
Senate clears FDA Modernization Act 3.0, aiming to align FDA regulations with nonclinical-testing reforms
The U.S. Senate on Dec. 16 passed the FDA Modernization Act 3.0 (S.355) by unanimous consent, sending legislation to the House that would require the FDA to update its regulations to reflect changes Congress enacted in 2022. The bill instructs HHS, acting through the FDA commissioner, to publish an interim final rule no later than…


